Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

124.15USD
12:35pm EST
Change (% chg)

$0.67 (+0.54%)
Prev Close
$123.48
Open
$123.82
Day's High
$128.79
Day's Low
$123.38
Volume
771,953
Avg. Vol
1,352,290
52-wk High
$196.47
52-wk Low
$119.37

Summary

Name Age Since Current Position

Jay Flatley

63 2016 Executive Chairman of the Board

Francis deSouza

45 2016 President, Chief Executive Officer, Director

Marc Stapley

46 2015 Chief Financial Officer, Executive Vice President, Chief Administrative Officer

Christian Henry

48 2015 Chief Commercial Officer, Executive Vice President

Tristan Orpin

50 2015 Executive Vice President - Clinical Genomics

Omead Ostadan

44 2015 Executive Vice President - Operations, Products and Strategy

Mostafa Ronaghi

47 2008 Chief Technology Officer, Senior Vice President

Charles Dadswell

57 2013 Senior Vice President, General Counsel, Secretary

Paula Dowdy

2016 Senior Vice President and General Manager

Paul Bianchi

54 2012 Senior Vice President - Human Resources

Nicholas Naclerio

54 2015 Senior Vice President - Corporate and Venture Development

Arthur Bowman

69 2016 Lead Independent Director

Philip Schiller

2016 Director

Frances Arnold

59 2016 Independent Director

Daniel Bradbury

54 2004 Independent Director

Karin Eastham

2004 Independent Director

Robert Epstein

60 2012 Independent Director

Roy Whitfield

62 2007 Independent Director

Biographies

Name Description

Jay Flatley

Mr. Jay T. Flatley is re-designated as Executive Chairman of the Board of the Company. Effective July 5, 2016. He was Chief Executive Officer, Director of Illumina, Inc. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech Inc. in 1998. He served in various other positions of increasing responsibility with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, Mr. Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Mr. Flatley also serves as a director of Coherent, Inc., a NASDAQ-listed provider of photonics-based solutions to commercial and scientific research markets. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.

Francis deSouza

Mr. Francis A. deSouza is President, Chief Executive Officer, Director of Illumina, Inc. Mr. deSouza has served as President since December 2013 and as a Director since January 2014. Prior to joining Illumina, Mr. deSouza was President, Products and Services, of Symantec Corporation, a NASDAQ-listed software technology company, from 2011 to 2013, and Mr. deSouza served as Symantec’s Senior Vice President, Enterprise Security Group, from 2009 to 2011. Prior to joining Symantec, from 2001 to 2006, he was Founder and Chief Executive Officer of IMlogic, Inc., an enterprise instant messaging software company that was acquired by Symantec in 2006, and Mr. deSouza served as Product Unit Manager, Real-time Collaboration Group, at Microsoft Corporation from 1998 to 2001. Prior to joining Microsoft, from 1997 to 1998, Mr. deSouza was co-founder and Chief Executive Officer of Flash Communications, an enterprise instant messaging company that was acquired by Microsoft in 1998. Mr. deSouza is Chairman of the board of directors of MedHelp International, a privately-held online health community. Mr. deSouza received a bachelor’s degree in electrical engineering and computer science with a minor in economics and a master’s degree from Massachusetts Institute of Technology.

Marc Stapley

Mr. Marc A. Stapley is Chief Financial Officer, Executive Vice President, Chief Administrative Officer of Illumina, Inc. Mr. Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems. Stapley began his career as an Auditor at Coopers & Lybrand. Mr. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.

Christian Henry

Mr. Christian O. Henry is no longer Chief Commercial Officer, Executive Vice President of Illumina, Inc., effective 31st, January 2017 (end of January 2017). He was Senior Vice President, General Manager - Genetic Analysis of Illumina Inc. He resigned as Chief Financial Officer effective January 4, 2012. He served as Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010; Senior Vice President and Chief Financial Officer from 2006 to 2009; 2006 – 2009: Senior Vice President and Chief Financial Officer;2005 – 2006: Vice President and Chief Financial Officer;2003 – 2005: chief financial officer for Tickets.com, a publicly traded, online ticket provider that was acquired by Major League Baseball Advanced Media, LP; Joined Illumina 2005.

Tristan Orpin

Mr. Tristan B. Orpin is no longer Executive Vice President - Clinical Genomics of Illumina, Inc., with effect from January 2017. He was Senior Vice President, Commercial Operations from 2007 – 2010; Vice President of Worldwide Sales from 2002 – 2007. He joined Illumina 2002.

Omead Ostadan

Mr. Omead Ostadan is Executive Vice President - Operations, Products and Strategy of the company Prior to that he served as Senior Vice President, Operations and Development. He is Senior Vice President, Product Development from 2011 to 2015.

Mostafa Ronaghi

Dr. Mostafa Ronaghi, Ph.D., is Chief Technology Officer, Senior Vice President of Illumina, Inc. Dr. Ronaghi joined Illumina in August 2008; 2002 – 2008: principal investigator at Stanford University, where Dr. Ronaghi focused on the development of novel tools for molecular diagnostic applications; 2007 – 2008: chairman and chief scientific officer for Avantome, Inc., a privately-held sequencing company co-founded by Dr. Ronaghi and acquired by Illumina in 2008.

Charles Dadswell

Mr. Charles E. Dadswell is Senior Vice President, General Counsel, Secretary of Illumina, Inc., since April 22, 2013. Mr. Dadswell joins Illumina with more than 20 years of leadership and legal experience at health care-focused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline. Mr. Dadswell holds a LLM in patent law and trade regulation from The George Washington University Law School, a JD from the Thomas M. Cooley Law School and a bachelor's in science from Ferris State University.

Paula Dowdy

Ms. Paula Dowdy is appointed as Senior Vice President and General Manager of the Company. Effective August 1, 2016. She joined Cisco 20 years ago and has spent the majority of her career in Europe. She has held numerous senior positions leading Cisco product and services groups for virtually all customer segments. In her most recent role, Paula led Cisco's go-to-market team for Cloud, Software, and Managed Services where she drove the incubation of innovative new solutions. Paula holds an MBA degree from Pepperdine University and a Bachelor of Arts degree from the University of California, Berkeley. Paula will officially join Illumina August 1, 2016.

Paul Bianchi

Mr. Paul L. Bianchi is Senior Vice President - Human Resources of Illumina, Inc., since September 5, 2012. From 2009 to 2012 he served as senior vice president, human resources at Risk Management Solutions, Inc. 2005 – 2009: principal at Strayer Consulting Group, Inc.

Nicholas Naclerio

Dr. Nicholas J. Naclerio, Ph.D., is Senior Vice President - Corporate and Venture Development of Illumina, Inc. He served as Senior Vice President, Corporate Development & General Manager - Enterprise Informatics from 2014 to 2015. He was Senior Vice President - Corporate and Venture Development of the company from 2011 to 2014. He was executive chairman of True Materials, a privately-held life science company that was acquired by Affymetrix, Inc. from 2007 – 2008; chief executive officer of ParAllele BioScience, Inc., a privately-held life science company that was acquired by Affymetrix, Inc. from 2003 – 2005. Mr. Naclerio became a named executive officer in fiscal 2011. He joined Illumina 2010.

Arthur Bowman

Mr. Arthur Blaine Bowman is Lead Independent Director of Illumina, Inc., since March 2016. He served as Independent Director between 2007 to 2016. Mr. Bowman was formerly the Chairman, President, and Chief Executive Officer of Dionex Corporation, a NASDAQ-listed manufacturer of analytical instruments. Mr. Bowman retired as President and Chief Executive Officer of Dionex in 2002 and as Chairman of the Board in 2005, and he remained a director of Dionex until its sale to Thermo Fisher Scientific Inc. in 2011. He joined Dionex in 1977 and was named President and Chief Executive Officer in 1980. Before joining Dionex, Mr. Bowman was a management consultant with McKinsey & Company, a management consulting firm, and a product engineer with Motorola Semiconductor Products Division, a communication equipment company. Mr. Bowman also serves as a director of Altera Corporation, a NASDAQ-listed provider of programmable logic solutions, and ProteinSimple, a privately-held life sciences company focused on protein research through the use of nanoproteomics. He also served as a past director of Molecular Devices Corporation, a NASDAQ-listed supplier of instruments and consumables for life science researchers, from 1985 until its sale to MDS Inc. in 2007, and of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Bowman received his B.S. in Physics from Brigham Young University and an M.B.A. from Stanford University.

Philip Schiller

Mr. Philip W. Schiller is Director of the Company. Schiller has more than 30 years of marketing and management experience, including over 25 at Apple in various marketing positions; as the Vice President of Product Marketing at Macromedia, Inc. of San Francisco, Calif.; as the Director of Product Marketing at FirePower Systems, Inc. of Menlo Park, Calif.; as an Information Technology Manager at Nolan, Norton & Company of Lexington, Mass.; and as a Programmer and Systems Analyst at Massachusetts General Hospital in Boston. He graduated with a B.S. in biology from Boston College.

Frances Arnold

Dr. Frances Arnold is Director of the Company. Dr. Arnold manages a research group at the California Institute of Technology and is the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology and Director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Dr. Arnold’s laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. She is the recipient of numerous honors, including induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold is an elected member of all three U.S. National Academics of Science, Medicine, and Engineering, as well as the American Academy of Arts and Sciences. Dr. Arnold received a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.

Daniel Bradbury

Mr. Daniel Mark Bradbury is an Independent Director of Illumina Inc., since January 2004. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2007 until its acquisition by Bristol-Myers-Squibb Company in 2012. From 2006 until 2012, he was a member of Amylin’s board of directors and served on its Finance and Risk Management Committee. Mr. Bradbury also served as Amylin’s President (2006-2007), Chief Operating Officer (2003-2006), and Executive Vice President (2000-2003). He joined Amylin in 1994 and also held officer-level positions in Corporate Development and Marketing. From 1984 to 1994, Mr. Bradbury held a number of sales and marketing positions at SmithKline Beecham Pharmaceuticals, a global pharmaceutical manufacturer. Mr. Bradbury serves as a director of Corcept Therapeutics Incorporated, a NASDAQ-listed biopharmaceutical company, Geron Corporation, a NASDAQ-listed biopharmaceutical company, BioMed Realty Trust, Inc., a NYSE-listed real estate investment trust, and Castle Biosciences Inc., a privately-held molecular diagnostics company. Mr. Bradbury also serves on the BioMed Ventures Advisory Committee, the Investor Growth Capital Advisory Committee, the Keck Graduate Institute’s Board of Trustees, the UCSD Rady School of Management’s Advisory Council, the University of Miami’s Innovation Corporate Advisory Council, and the University of Miami’s Diabetes Research Institute Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.

Karin Eastham

Ms. Karin Eastham, CPA, is Independent Director of Illumina, Inc., since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc., a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc., a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc., a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Robert Epstein

Dr. Robert S. Epstein, M.D., is Independent Director of Illumina, Inc., since November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc., a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland.

Roy Whitfield

Mr. Roy A. Whitfield is Independent Director of Illumina, Inc., since January 2007. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation (formerly Incyte Genomics), a NASDAQ-listed drug discovery and development company he co-founded in 1991. From 1993 to 2001, Mr. Whitfield served as its Chief Executive Officer and, from November 2001 until his retirement in June 2003, as its Chairman. Mr. Whitfield remains on the board of Incyte Corporation. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Earlier, Mr. Whitfield spent seven years with the Boston Consulting Group’s international consulting practice. In addition to serving on the Incyte Board, since 2000 he has served as a director of Nektar Therapeutics, a NASDAQ-listed clinical-stage biopharmaceutical company, and he also serves as a director of Station X Inc., a privately-held developer of software products for analyzing largescale human genome information. Mr. Whitfield also served as a past director of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Whitfield received a B.S. in Mathematics from Oxford University and an M.B.A. from Stanford University.